+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07367(IGFBP5 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07367(IGFBP5 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The insulin-like growth factor-binding protein 5 (IGFBP5) antibody is a critical tool for studying the role of IGFBP5. a member of the IGFBP family that modulates the bioavailability and activity of insulin-like growth factors (IGFs) in various physiological and pathological processes. IGFBP5 binds IGF-1 and IGF-2 with high affinity, regulating cell proliferation, differentiation, and apoptosis by controlling IGF-receptor interactions. It also exhibits IGF-independent functions, including interactions with extracellular matrix components and nuclear localization to influence gene expression. Dysregulation of IGFBP5 is implicated in cancers (e.g., breast, prostate), metabolic disorders, and bone diseases.

The IGFBP5 antibody is widely used in research applications such as Western blotting, immunohistochemistry (IHC), and ELISA to detect protein expression, localization, and interactions in tissues or cell lines. It aids in understanding IGFBP5’s dual role in promoting or suppressing tumor growth, depending on cellular context, and its involvement in osteoporosis and wound healing. Commercial antibodies are typically raised in rabbits or mice, targeting specific epitopes (e.g., N-terminal, C-terminal domains). Validation includes testing for cross-reactivity with other IGFBPs. Researchers must select antibodies validated for their specific experimental models to ensure reliability. Its clinical relevance extends to potential biomarker discovery and therapeutic targeting in IGF-axis-related diseases.